Progress of B-cell mature antigen-targeted chimeric antigen receptor T-cell therapy for multiple myeloma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 68-72, 2022.
Artículo
en Chino
| WPRIM
| ID: wpr-929735
ABSTRACT
Cell therapy as represented by chimeric antigen receptor T-cell (CAR-T) therapy has made many breakthroughs in the treatment of multiple myeloma (MM), especially autologous CAR-T targeting B-cell mature antigen (BCMA), bispecific CAR-T and universal CAR-T have achieved good curative effect in many clinical studies of MM. A variety of clinical studies with remarkable results were updated at the 63rd American Society of Hematology Annual Meeting.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Journal of Leukemia & Lymphoma
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS